Teva Pharmaceutical Industries Management
Management criteria checks 4/4
Teva Pharmaceutical Industries' CEO is Richard Francis, appointed in Jan 2023, has a tenure of 3.08 years. total yearly compensation is $15.52M, comprised of 10.3% salary and 89.7% bonuses, including company stock and options. directly owns 0.011% of the company’s shares, worth $4.48M. The average tenure of the management team and the board of directors is 3.3 years and 8.6 years respectively.
Key information
Richard Francis
Chief executive officer
US$15.5m
Total compensation
| CEO salary percentage | 10.31% |
| CEO tenure | 3.1yrs |
| CEO ownership | 0.01% |
| Management average tenure | 3.3yrs |
| Board average tenure | 8.6yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | n/a | n/a | US$1b |
| Sep 30 2025 | n/a | n/a | US$713m |
| Jun 30 2025 | n/a | n/a | -US$157m |
| Mar 31 2025 | n/a | n/a | -US$1b |
| Dec 31 2024 | US$16m | US$2m | -US$2b |
| Sep 30 2024 | n/a | n/a | -US$959m |
| Jun 30 2024 | n/a | n/a | -US$453m |
| Mar 31 2024 | n/a | n/a | -US$478m |
| Dec 31 2023 | US$26m | US$2m | -US$559m |
Compensation vs Market: Richard's total compensation ($USD15.52M) is about average for companies of similar size in the US market ($USD13.43M).
Compensation vs Earnings: Richard's compensation has been consistent with company performance over the past year.
CEO
Richard Francis (57 yo)
Mr. Richard D. Francis is Non-Executive Director of Purespring Therapeutics Limited. He serves as President and Chief Executive Officer at Teva Pharmaceutical Industries Limited since January 01, 2022 and...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.1yrs | US$15.52m | 0.011% $ 4.5m | |
| Executive VP & CFO | 6.2yrs | US$6.18m | 0.035% $ 14.7m | |
| Executive Vice President of European Commercial | 8.3yrs | US$5.43m | 0.0042% $ 1.8m | |
| Executive VP of Global R&D and Chief Medical Officer | 3.5yrs | US$5.75m | no data | |
| Executive VP of US Commercial & Head of Innovative Franchise | 2.3yrs | US$5.22m | 0.0056% $ 2.3m | |
| Executive Vice President of Global Operations | 1.7yrs | no data | 0.00087% $ 362.6k | |
| Senior VP & Chief Accounting Officer | 4.3yrs | no data | 0.00049% $ 204.2k | |
| Senior Vice President of Investor Relations & Competitive Intelligence | no data | no data | no data | |
| Senior Vice President | 3.6yrs | no data | no data | |
| Executive VP & Chief Legal Officer | 1.9yrs | no data | 0.0011% $ 475.2k | |
| Executive VP & CHRO | 1.5yrs | no data | 0.00059% $ 245.9k | |
| Senior Vice President of Investor Relations | no data | no data | no data |
Experienced Management: TEVJ.F's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | no data | US$15.52m | 0.011% $ 4.5m | |
| Independent Chairman of the Board | 11.1yrs | US$539.99k | 0.037% $ 15.5m | |
| Independent Director | 17.1yrs | US$339.99k | 0.18% $ 76.4m | |
| Independent Director | 10.4yrs | US$354.99k | 0.010% $ 4.2m | |
| Independent Director | 8.6yrs | US$339.99k | 0.0092% $ 3.8m | |
| Independent Director | 10.4yrs | US$329.99k | 0.0099% $ 4.1m | |
| Independent Director | 5.7yrs | US$334.99k | 0.0064% $ 2.7m | |
| Independent Director | 1.2yrs | US$93.32k | 0.00042% $ 175.1k | |
| Independent Director | 4.3yrs | US$329.99k | 0.0051% $ 2.1m | |
| Independent Director | 8.6yrs | US$334.99k | 0.0092% $ 3.8m | |
| Independent Director | 7.7yrs | US$319.99k | 0.0085% $ 3.6m | |
| Independent Director | 2.4yrs | US$309.99k | 0.0020% $ 816.9k |
Experienced Board: TEVJ.F's board of directors are considered experienced (8.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/04 06:34 |
| End of Day Share Price | 2026/01/26 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Teva Pharmaceutical Industries Limited is covered by 46 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Balaji Prasad | Barclays |
| Glen Santangelo | Barclays |